MENLO PARK, Calif., Oct. 12, 2015 /PRNewswire/ -- Jane S. Lebkowski, Ph.D., President of R&D and Chief Scientific Officer of Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, will participate in a BioPharma Dealmakers webcast, sponsored in part by Asterias Biotherapeutics, featuring four companies developing regenerative medicine. Dr. Lebkowski will discuss the progress to date for the Company's transformative technology platforms, AST-VAC1 and AST-VAC2, which address opportunities across multiple cancers, stages of cancer, and combinations therapies and AST-OPC1, which is focused on the treatment of spinal cord injury and other neurodegenerative diseases.
The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am ET on October 14th. Webcast registration.
The webcast will explore some of the technologies and companies driving this rapidly developing field of regenerative medicine. Participants will learn about new approaches that have been developed to:
The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this highly innovative area of regenerative medicine.
Dr. Jane S. Lebkowski, has been actively involved in the development of cell and gene therapies since 1986. Other webcast participants include:
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's proprietary, industry leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
Forward Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.
SOURCE Asterias Biotherapeutics, Inc.